Literature DB >> 7618252

Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.

R Hofmann-Lehmann1, E Holznagel, A Aubert, P Ossent, M Reinacher, H Lutz.   

Abstract

The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n = 15) were previously infected with the Swiss isolate FIV Zurich 2. The second half of the animals (n = 15) served as non-infected controls. Eighteen (nine FIV-negative, nine FIV-positive) vaccinated and 12 (six FIV-negative, six FIV-positive) non-vaccinated cats were intraperitoneally challenged with FeLV A. Seventeen of 18 vaccinated cats were protected against persistent viremia, while ten of 12 non-vaccinated controls became infected. An increase of antibodies against FeLV SU was found in all protected cats after the challenge exposure. No difference in vaccine efficacy was found between FIV-negative and FIV-positive animals. The whole group of cats was observed for over 3 years. There were no further vaccinations during this period. CD4+ and CD8+ cell subsets, clinical outcome and time of survival of the cats were recorded. FIV-negative and FIV-positive animals were kept in two different rooms. However, FeLV-negative and FeLV viremic cats were housed together in both rooms in order to imitate a natural FeLV exposure situation. Anti-recombinant FeLV SU antibodies were measured by enzyme-linked immunosorbent assay. Although a continuous decline of antibodies was found in FeLV vaccinated cats, they remained protected against constant FeLV challenge for over 3 years. FIV infection had a stronger effect on the depression of the CD4+:CD8+ ratio than FeLV infection. Within the group of FIV-positive cats, the FeLV-vaccinated animals had significantly better survival rates as well as better clinical and laboratory parameters. FIV- and FeLV-coinfected cats showed the lowest CD4+:CD8+ ratio, mainly caused by decreased CD4+ lymphocyte counts. CD8+ lymphocytes with strong fluorescence (CD8(high)) disappeared and cells with weak fluorescence (CD8(low)) appeared instead. Prevention of coinfection by immunizing FIV-positive cats against FeLV infection improved the clinical outcome and prolonged the cat's life expectancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618252      PMCID: PMC7119625          DOI: 10.1016/0165-2427(94)07012-v

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  16 in total

1.  Development of a genetically engineered vaccine against feline leukemia virus infection.

Authors:  C R Kensil; C Barrett; N Kushner; G Beltz; J Storey; U Patel; J Recchia; A Aubert; D Marciani
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

2.  Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats.

Authors:  D J Marciani; C R Kensil; G A Beltz; C H Hung; J Cronier; A Aubert
Journal:  Vaccine       Date:  1991-02       Impact factor: 3.641

3.  Clinical staging of feline immunodeficiency virus infection.

Authors:  T Ishida; I Tomoda
Journal:  Nihon Juigaku Zasshi       Date:  1990-06

4.  Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.

Authors:  R Lehmann; M Franchini; A Aubert; C Wolfensberger; J Cronier; H Lutz
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

5.  Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections.

Authors:  J E Barlough; C D Ackley; J W George; N Levy; R Acevedo; P F Moore; B A Rideout; M D Cooper; N C Pedersen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  Preparation of CD8bright and CD8dim lymphocyte populations using two positive selection methods in tandem.

Authors:  H E Prince; S Bermudez; S Plaeger-Marshall
Journal:  J Immunol Methods       Date:  1993-10-15       Impact factor: 2.303

8.  Frequency and significance of feline leukemia virus infection in necropsied cats.

Authors:  M Reinacher; G Theilen
Journal:  Am J Vet Res       Date:  1987-06       Impact factor: 1.156

9.  Randomized blind trial of a commercial FeLV vaccine.

Authors:  R V Pollock; J M Scarlett
Journal:  J Am Vet Med Assoc       Date:  1990-02-15       Impact factor: 1.936

10.  Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.

Authors:  R Lehmann; B von Beust; E Niederer; M A Condrau; W Fierz; A Aubert; C D Ackley; M D Cooper; M B Tompkins; H Lutz
Journal:  Vet Immunol Immunopathol       Date:  1992-12       Impact factor: 2.046

View more
  11 in total

1.  CVMA position statement on vaccine protocols ill considered.

Authors:  M Scherk
Journal:  Can Vet J       Date:  1998-08       Impact factor: 1.008

2.  Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes.

Authors:  J N Flynn; C A Cannon; D Sloan; J C Neil; O Jarrett
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 3.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

4.  Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma.

Authors:  A Katrin Helfer-Hungerbuehler; Valentino Cattori; Felicitas S Boretti; Pete Ossent; Paula Grest; Manfred Reinacher; Manfred Henrich; Eva Bauer; Kim Bauer-Pham; Eva Niederer; Edgar Holznagel; Hans Lutz; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2010-02-19       Impact factor: 4.602

5.  Epizootiology and management of feline leukemia virus in the Florida puma.

Authors:  Mark W Cunningham; Meredith A Brown; David B Shindle; Scott P Terrell; Kathleen A Hayes; Bambi C Ferree; R T McBride; Emmett L Blankenship; Deborah Jansen; Scott B Citino; Melody E Roelke; Richard A Kiltie; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Wildl Dis       Date:  2008-07       Impact factor: 1.535

6.  The role of in vitro-induced lymphocyte apoptosis in feline immunodeficiency virus infection: correlation with different markers of disease progression.

Authors:  E Holznagel; R Hofmann-Lehmann; C M Leutenegger; K Allenspach; S Huettner; U Forster; E Niederer; H Joller; B J Willett; U Hummel; G L Rossi; J Schüpbach; H Lutz
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Putative progressive and abortive feline leukemia virus infection outcomes in captive jaguarundis (Puma yagouaroundi).

Authors:  Claudia Filoni; A Katrin Helfer-Hungerbuehler; José Luiz Catão-Dias; Mara Cristina Marques; Luciana Neves Torres; Manfred Reinacher; Regina Hofmann-Lehmann
Journal:  Virol J       Date:  2017-11-17       Impact factor: 4.099

8.  Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax® Lv-K and Fel-O-Vax® 5).

Authors:  Mark Westman; Jacqueline Norris; Richard Malik; Regina Hofmann-Lehmann; Yasmin A Parr; Emma Armstrong; Mike McDonald; Evelyn Hall; Paul Sheehy; Margaret J Hosie
Journal:  Viruses       Date:  2021-02-03       Impact factor: 5.048

9.  Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro.

Authors:  A Katrin Helfer-Hungerbuehler; Jimit Shah; Theres Meili; Eva Boenzli; Pengfei Li; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2021-08-18       Impact factor: 5.048

Review 10.  Feline leukaemia. ABCD guidelines on prevention and management.

Authors:  Hans Lutz; Diane Addie; Sándor Belák; Corine Boucraut-Baralon; Herman Egberink; Tadeusz Frymus; Tim Gruffydd-Jones; Katrin Hartmann; Margaret J Hosie; Albert Lloret; Fulvio Marsilio; Maria Grazia Pennisi; Alan D Radford; Etienne Thiry; Uwe Truyen; Marian C Horzinek
Journal:  J Feline Med Surg       Date:  2009-07       Impact factor: 2.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.